| Literature DB >> 15811840 |
Jean M Cox-Ganser1, Sandra K White, Rebecca Jones, Ken Hilsbos, Eileen Storey, Paul L Enright, Carol Y Rao, Kathleen Kreiss.
Abstract
We conducted a study on building-related respiratory disease and associated social impact in an office building with water incursions in the northeastern United States. An initial questionnaire had 67% participation (888/1,327). Compared with the U.S. adult population, prevalence ratios were 2.2-2.5 for wheezing, lifetime asthma, and current asthma, 3.3 for adult-onset asthma, and 3.4 for symptoms improving away from work (p < 0.05). Two-thirds (66/103) of the adult-onset asthma arose after occupancy, with an incidence rate of 1.9/1,000 person-years before building occupancy and 14.5/1,000 person-years after building occupancy. We conducted a second survey on 140 respiratory cases, 63 subjects with fewer symptoms, and 44 comparison subjects. Health-related quality of life decreased with increasing severity of respiratory symptoms and in those with work-related symptoms. Symptom status was not associated with job satisfaction or how often jobs required hard work. Respiratory health problems accounted for one-third of sick leave, and respiratory cases with work-related symptoms had more respiratory sick days than those without work-related symptoms (9.4 vs. 2.4 days/year; p < 0.01). Abnormal lung function and/or breathing medication use was found in 67% of respiratory cases, in 38% of participants with fewer symptoms, and in 11% of the comparison group (p < 0.01), with similar results in never-smokers. Postoccupancy-onset asthma was associated with less atopy than preoccupancy-onset asthma. Occupancy of the water-damaged building was associated with onset and exacerbation of respiratory conditions, confirmed by objective medical tests. The morbidity and lost work time burdened both employees and employers.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15811840 PMCID: PMC1278490 DOI: 10.1289/ehp.7559
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Demographics of 888 participants in the September 2001 questionnaire survey.
| Characteristic | Proportion or measure |
|---|---|
| Female (%) | 59 |
| Age [years (mean ± SD)] | 46 ± 9 |
| Race (%) | |
| White | 74 |
| Black | 19 |
| Hispanic | 6 |
| Building occupancy [years (mean ± SD)] | 6 ± 2 |
| Current smoker (%) | 14 |
| Never smoker (%) | 62 |
Comparison of health outcomes prevalences with NHANES III (NCHS 1996).
| Standardized questions | Building prevalence [% ( | Prevalence ratio | 95% CI |
|---|---|---|---|
| Asthma ever | 17.7 (143/810) | 2.2 | 1.9–2.6 |
| Asthma current | 12.8 (103/804) | 2.4 | 2.0–3.0 |
| Wheezing or whistling in your chest in the last 12 months | 35.9 (291/811) | 2.5 | 2.2–2.8 |
| Stuffy, itchy, or runny nose in the last 12 months. | 79.3 (643/811) | 1.5 | 1.4–1.6 |
| Watery, itchy eyes in the last 12 months | 63.4 (510/804) | 1.6 | 1.4–1.7 |
| Wheezing, nose, or eye symptoms better on days off work | 72.1 (468/649) | 3.4 | 3.1–3.7 |
The prevalence ratios were adjusted for age, sex, race, and smoking category; missing information on these characteristics led to comparisons based on fewer than the total 888 participants.
Our question included sneezing.
The prevalence of work-related lower respiratory symptoms that occurred frequently in the previous 4 weeks, compared to U.S. office workers.
| Prevalence (%) | Prevalence ratio | 95% CI | |
|---|---|---|---|
| Wheezing | 6.9 | 2.9 | 2.2–3.7 |
| Coughing attacks | 14.8 | 2.7 | 2.3–3.2 |
| Chest tightness | 11.3 | 4.7 | 3.8–5.7 |
| Shortness of breath | 9.6 | 4.6 | 3.7–5.7 |
The prevalence of the 888 study participants compared with results from 41 nonproblem buildings (Apte et al. 2000).
Mean number of lower respiratory symptoms and prevalence of work-related symptoms in the last 4 weeks by asthma status and onset period.
| Postoccupancy-onset asthma | Preoccupancy adult-onset asthma | Childhood-onset asthma | No reported asthma | |
|---|---|---|---|---|
| Number of lower respiratory symptoms (mean ± SD) | 1.7 ± 1.6 | 1.1 ± 1.3 | 0.7 ± 1.3 | 0.5 ± 0.9 |
| Work-related lower respiratory symptoms [ | 34/66 (52) | 15/37 (41) | 8/30 (27) | 169/731 (23) |
Lower respiratory symptoms include wheeze, cough, chest tightness, and shortness of breath.
Means with the same letter are not significantly different at α = 0.05, using Duncan’s multiple-range test.
Cochran-Armitage trend test p < 0.0001.
Demographics of June 2002 participants by respiratory symptom status.
| Respiratory case group ( | Fewer symptoms group ( | Comparison group ( | |
|---|---|---|---|
| Female (%) | 73 | 44 | 59 |
| Age [years (mean ± SD)] | 47 ± 8 | 46 ± 9 | 46 ± 8 |
| Occupancy duration [years (mean ± SD)] | 7 ± 2 | 7 ± 2 | 7 ± 2 |
| Current smoker (%) | 17 | 6 | 9 |
| Never smoker (%) | 56 | 70 | 70 |
Due to missing values, age and duration of occupancy in respiratory case group are based on 137 participants. For age, n = 62 in the fewer symptoms group and n = 42 in the comparison group.
p = 0.0004 by Chi-square test on sex.
Breathing test results for participants, stratified by symptom status in June 2002.
| Variable | Respiratory cases group | Fewer symptoms group | Comparison group |
|---|---|---|---|
| Spirometry testing [% ( | |||
| Abnormal | 24 (31/131) | 13 (8/62) | 7 (3/42) |
| Obstructed or mixed | 15 (20/131) | 6 (4/62) | 7 (3/42) |
| Restriction (low FVC) | 8 (11/131) | 6 (4/62) | 0 (0/42) |
| Percent predicted FEV1 (mean ± SD) | 92 ± 16 | 96 ± 17 | 103 ± 12 |
| Percent predicted FVC (mean ± SD) | 94 ± 14 | 97 ± 16 | 103 ± 11 |
| Methacholine challenge testing [% ( | |||
| Abnormal (< 16 mg/mL) | 19 (19/99) | 20 (10/51) | 6 (2/36) |
| < 4 mg/mL (BHR) | 6 (6/99) | 8 (4/51) | 0 (0/36) |
| > 4 and < 16 mg/mL (borderline BHR) | 13 (13/99) | 12 (6/51) | 6 (2/36) |
| Bronchodilator testing positive [% ( | 18 (2/11) | ND | ND |
| Abnormal methacholine challenge or bronchodilator tests [% ( | 19 (21/110) | 20 (10/51) | 6 (2/36) |
| Any abnormal lung function test [% ( | 39 (44/114) | 29 (16/55) | 11 (4/37) |
ND, not done.
Two invalid tests by the symptomatic participants were not included.
Across the row there was a significant Cochran-Armitage trend test (p < 0.01); the significant differences by symptom status remained after adjusting for smoking category (Cochran-Mantel-Haenszel test; p < 0.05).
In a linear regression model adjusting for smoking category, there was a significant effect of symptom status (p < 0.01); the group meeting the respiratory case definition had a lower mean percent predicted FEV1 than either of the other two groups.
In a linear regression model adjusting for smoking category, there was a significant effect of symptom status (p < 0.01); the group that met the respiratory case definition had a lower mean percent predicted FVC than the asymptomatic group.
Participants who had either a negative spirometry or a negative methacholine/bronchodilator test and who had not done the other tests were excluded.
Across the row there was a significant Cochran-Armitage trend test (p < 0.01); the significant differences by symptom status remained after adjusting for smoking category (Cochran-Mantel-Haenszel test; p < 0.01).
Medication usage and combined medication usage and abnormal lung function [% (n)] stratified by symptom status in June 2002.
| Respiratory cases group | Fewer symptoms | Comparison group | |
|---|---|---|---|
| Any medication for breathing problems | 46 (65/140) | 13 (8/63) | 2 (1/44) |
| Oral steroids | 21 (29/140) | 8 (5/63) | 2 (1/44) |
| Inhaled steroids | 19 (27/140) | 2 (1/63) | 0 (0/44) |
| Beta-agonists | 28 (39/140) | 2 (1/63) | 0 (0/44) |
| Positive for any medication for breathing problems or an abnormal lung function test | 67 (83/124) | 38 (21/55) | 11 (4/37) |
Across all rows there were significant Cochran-Armitage trend tests (p < 0.01); the significant differences by symptom status remained after adjusting for smoking category (Cochran-Mantel-Haenszel tests; p < 0.01).
Figure 1Quality-of-life comparisons among symptom groups. **p < 0.01, Cochran-Armitage trend test.
Figure 2Quality of life in the respiratory case group and the fewer symptoms group, stratified by work-relatedness of symptoms. *p < 0.05 and **p < 0.01, Chi-square test.
Figure 3Allergy skin test results by asthma diagnosis. *p < 0.05 and **p < 0.01, Chi-square test.